
Baxter (BAX) Stock Forecast & Price Target
Baxter (BAX) Analyst Ratings
Bulls say
Baxter International has demonstrated a solid financial trajectory, particularly in its Healthcare Systems & Technologies segment, which experienced sales growth of approximately 6% in the first quarter of 2025 and 2% in the second quarter, with projected growth rates of 4% and 2% for the third and fourth quarters, respectively. Additionally, the company has implemented pricing initiatives that are expected to contribute approximately 100 basis points to sales growth in 2024 and 2025, enhancing revenue stability. The strategic acquisition of Hillrom has further diversified Baxter's portfolio, positioning it favorably in the healthcare market and supporting its overall growth prospects.
Bears say
Baxter International has experienced a significant downturn in its financial performance, as evidenced by disappointing results in the second quarter of 2025, where sales, margins, and earnings per share all fell below consensus expectations. The company has struggled through a challenging operational period from 2021 to 2023, marked by a combination of external factors and internal missteps that resulted in mixed quarterly performances and multiple negative guidance revisions. Moreover, sales softness, manufacturing inefficiencies, and an unfavorable product mix have led to gross margins of 40.7%, which fell short of both the company’s and consensus estimates, along with operating margins of 15.1% that also missed consensus expectations by over 100 basis points.
This aggregate rating is based on analysts' research of Baxter and is not a guaranteed prediction by Public.com or investment advice.
Baxter (BAX) Analyst Forecast & Price Prediction
Start investing in Baxter (BAX)
Order type
Buy in
Order amount
Est. shares
0 shares